Thank you to all of those who attended our first virtual symposium. It was a great success and we are excited to host another in early 2021. If you are interested in presenting, please email Alicia at email@example.com.
For those who were unable to attend, you can view the recording of the session here. Listed below are the start times of the individual presentations and their titles:
Dr. Sam Silver presents his trial, Promoting Kidney Recovery after Acute Kidney Injury Receiving Dialysis, at 11:20.
Dr. Bhanu Prasad presents his trial, Renal denervation in patients with loin pain hematuria syndrome – a feasibility study, at 43:05.
Dr. Ron Wald gives an update on the PHOSPHATE trial, Pragmatic randomized trials of High Or Standard PHosphAte Targets in End-stage kidney disease, at 1:20:50.
Dr. Michael Walsh discuss the recruitment challenges with his multi-centre, multi-country trial – ACHIEVE, Aldosterone Blockade for Health Improvement Evaluation in End Stage Renal Disease, at 1:58:40.
If you’re a patient with vasculitis or kidney disease that lives in Canada, the United Kingdom, or the United States, please help us out by taking 15 minutes to complete a survey regarding patient value and preferences about plasma exchange in ANCA associated vasculitis.
All responses are anonymous. Your answers will help patients and doctors with shared decision making about plasma exchange in patients with vasculitis and kidney disease as well as inform clinical practice guidelines. Thanks!
Dr. David Collister, CNTN Scientific Operations and Executive committee member, is co-principal investigator on a study, “CANNAbis for the treatment of symptoms in advanced CKD and dialysis: a patient survey (CANNA-CKD)”
This study is an online survey of adults with kidney disease (including chronic kidney disease, dialysis or transplant). The survey consists of 15 questions and should take no longer than 10 minutes to complete. It collects information about your use of recreation and medicinal cannabis use.
The goal of this survey is to determine the recreational and medicinal cannabis experiences of patients with advanced chronic kidney disease or those on dialysis. We would also like to evaluate your willingness to participate in future studies of cannabis for symptoms related to kidney disease.
All responses are anonymous and it does not collect any personal health information. The results of this survey (and a physician survey) will be used to determine which symptoms to pursue funding for clinical trials of cannabis in patients with kidney disease. The results of the physician survey were recently published and can be found here.
The survey is available at https://www.surveymonkey.com/r/TCCWJFX. For questions related to the survey, please contact Dr. Collister at firstname.lastname@example.org.